Gut microbiome in heart failure and aortic stenosis

Area of Science:

• Gastroenterology
• Cardiology
• Microbiology

Background:

• Gut microbiome alterations are implicated in various diseases.
• Congestive heart failure (HF) patients exhibit intestinal edema, bacterial overgrowth, and increased production of harmful substances like trimethylamine N-oxide (TMAO) and lipopolysaccharide (LPS).
• These gut-derived toxins contribute to HF deterioration and higher mortality rates.

Purpose of the Study:

• To explore the connection between the gut microbiome and heart failure, termed the heart-bowel axis.
• To investigate the role of TMAO and LPS in HF progression and mortality.
• To examine the link between LPS, inflammation, and the osteogenic response in aortic stenosis.

Main Methods:

• Literature review and synthesis of existing research on the gut microbiome, HF, TMAO, LPS, and aortic stenosis.
• Analysis of the impact of gut-derived toxins on cardiovascular disease development and progression.

Main Results:

• Elevated TMAO levels in HF patients correlate with increased long-term mortality, independent of traditional risk factors.
• Intestinal LPS contributes to inflammation and the osteogenic response in aortic stenosis via valve interstitial cells.
• The gut microbiome plays a significant role in the pathogenesis and progression of HF and aortic stenosis.

Conclusions:

• The gut microbiome represents a critical factor in the development and exacerbation of heart failure.
• TMAO and LPS are key mediators in the heart-bowel axis, impacting HF prognosis and aortic stenosis.
• Further research into the gut microbiome may uncover novel therapeutic targets for cardiovascular diseases like HF and aortic stenosis.